Monoclonal antibodyFDA-approvedSecond-line
Nivolumab + Ipilimumab
How it works
Blocks PD-1 and CTLA-4, proteins that normally help cancer cells evade the immune system, allowing the immune system to attack cancer cells more effectively.
Cancer types
Melanoma— All patients
Efficacy
In clinical trials, around 58% of patients achieved an objective response, with a median overall survival of approximately 11.5 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.